ALK-Abelló Reports Positive Results from Mid-stage Trial of Peanut Allergy Treatment
Idag, 17:51
11:51 AM EDT, 04/20/2026 (MT Newswires) -- ALK-Abelló (ALK-B.CO) said Monday its investigational sublingual immunotherapy tablet for the treatment of peanut allergy in patients aged four to 65 years showed a "successful outcome"in its mid-stage clinical trial.
In the phase 2 Alliance trial, which involved 150 patients, the once-daily tablet demonstrated clear dose-dependent and statistically significant efficacy across multiple efficacy endpoints after 24 weeks of maintenance treatment.
The Danish pharmaceutical company expects the phase 3 study to start around year-end, pending regulatory feedback on the final trial design.
Ämnen i artikeln
ALK-Abelló Reports Positive Results from Mid-stage Trial of Peanut Allergy Treatment
Idag, 17:51
11:51 AM EDT, 04/20/2026 (MT Newswires) -- ALK-Abelló (ALK-B.CO) said Monday its investigational sublingual immunotherapy tablet for the treatment of peanut allergy in patients aged four to 65 years showed a "successful outcome"in its mid-stage clinical trial.
In the phase 2 Alliance trial, which involved 150 patients, the once-daily tablet demonstrated clear dose-dependent and statistically significant efficacy across multiple efficacy endpoints after 24 weeks of maintenance treatment.
The Danish pharmaceutical company expects the phase 3 study to start around year-end, pending regulatory feedback on the final trial design.
Ämnen i artikeln
Banker
Analys
Banker
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
-160x160.jpg&w=3840&q=75)
